Anlotinib, another novel orally active tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR, and c-kit, was assessed in combination with sintilimab, a PD-1 inhibitor, in a phase II trial involving patients with unresectable iCCA. This evidence concerns the gene KDR and infantile convulsions and choreoathetosis.